Data from patients showing that Cdc42 is overexpressed with high incidence in colorectal adenocarcinoma biopsies [18] and the findings in this study, support the notion that Cdc42 inhibition could be used as a therapeutic strategy to fight colorectal cancer. This evidence concerns the gene CDC42 and colorectal adenocarcinoma.